-
1.发明申请Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds 有权具有MCH拮抗活性的酰胺化合物和包含这些化合物的药物公开(公告)号：US20040152742A1
公开(公告)日：2004-08-05
申请号：US10699089
申请日：2003-10-31
发明人： Dirk Stenkamp , Stephan Georg Mueller , Gerald Juergen Roth , Philipp Lustenberger , Klaus Rudolf , Thorsten Lehmann-Lintz , Kirsten Arndt , Ralf Lotz , Martin Lenter , Heike-Andrea Wieland
IPC分类号： A61K031/54 , A61K031/535 , A61K031/497 , A61K031/44
CPC分类号： C07D213/30 , C07C233/29 , C07C235/24 , C07C237/04 , C07C255/60 , C07C275/32 , C07C2601/14 , C07D207/09 , C07D207/20 , C07D209/08 , C07D211/46 , C07D211/62 , C07D213/56 , C07D295/03 , C07D295/088 , C07D295/13 , C07D307/42 , C07D333/16
摘要： The present invention relates to amide compounds of general formula I 1 wherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
摘要翻译： 本发明涉及通式I的酰胺化合物，其中基团和残基A，B，b，W，X，Y，Z，R 1，R 2和R 3具有权利要求书中给出的含义 此外，本发明涉及含有根据本发明的至少一种酰胺的药物组合物。 鉴于MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖，贪食症，厌食症，食欲过盛和糖尿病。
-
2.发明申请Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 审中-公开黄嘌呤衍生物，其制备及其作为药物组合物的用途公开(公告)号：US20040087587A1
公开(公告)日：2004-05-06
申请号：US10693069
申请日：2003-10-24
发明人： Frank Himmelsbach , Michael Mark , Matthias Eckhardt , Elke Langkopf , Roland Maier , Ralf Lotz
IPC分类号： A61K031/5377 , A61K031/522 , C07D473/02
CPC分类号： C07D473/08 , C07D473/04 , C07D473/06 , C07D473/10 , C07D473/12
摘要： The present invention relates to substituted xanthines of general formula 1 wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 本发明涉及通式其中R 1至R 4如权利要求1所定义的取代黄嘌呤，其互变异构体及其立体异构体，其混合物，其前体药物及其盐具有有价值的药理学性质，特别是 对二肽基肽酶-IV（DPP-IV）的活性具有抑制作用。
-
搜索结果
2 条记录 (耗时 0.019 秒)
